RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaN/A

Registered title, quoted from ClinicalTrials.gov

Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Guangxi Medical University; 13 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 14

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  2. Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
  3. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  4. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  5. Study siteFourth Affiliated Hospital of Guangxi Medical University广西医科大学第四附属医院LiuzhouHospital page
  6. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  7. Study siteFujian Provincial Hospital福建省立医院FuzhouHospital page
  8. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  9. Study siteHainan Cancer Hospital海南省肿瘤医院HaikouHospital page
  10. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  11. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
  12. Study siteWuzhou Red Cross Hospital梧州市红十字会医院WuzhouHospital page
  13. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  14. Study siteZhejiang Provincial People's Hospital浙江省人民医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05892354, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated,WHO type II or III);

    Inclusion criterion 3

  3. Newly diagnosed stage III-IVa (8th AJCC/UICC stage) NPC patients;

    Inclusion criterion 4

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

    Inclusion criterion 1

  5. History of human immunodeficiency virus (HIV) or active hepatitis B/C virus infection;

    Exclusion criterion 12

  6. Age 18-70 years old, male or non-pregnant women;

    Inclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05892354, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
  • Age 18-70 years old, male or non-pregnant women;
  • Pathologically confirmed non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated,WHO type II or III);
  • Newly diagnosed stage III-IVa (8th AJCC/UICC stage) NPC patients;
  • The levels of major organ function meet the following criteria:

(1)Hematology: WBC ≥ 3.0 × 10\^9/L, ANC ≥ 1.5 × 10\^9/L, PLT ≥ 100 × 10\^9/L, HGB ≥ 90 g/L; (2) Liver function: ALT, AST≤2.5 times the upper limit of normal (ULN), total bilirubin ≤ 1.5 × ULN; (3) Renal function: BUN and CRE ≤ 1.5 × ULN or an estimated glomerular filtration rate (eGFR) ≥ 60 ml/min (calculated using the Cockcroft-Gault equation); (4) Adequate coagulation function: defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times the ULN; (5) Normal levels of cardiac enzymes; 6. The patient has signed informed consent forms and is able to comply with the study's planned visits, treatment plans, and laboratory tests.

Exclusion Criteria:

  • History of investigational Oral Impact®/ENSURE® use within the month prior to enrollment;
  • Known allergy or intolerance to any component of investigational Oral Impact®/ENSURE® or related chemotherapy drugs;
  • Poor glycemic control in patients with diabetes;
  • Patients with autoimmune diseases;
  • Patients with active infections;
  • Patients who have received radiation therapy or other anti-tumor treatments in the past;
  • Patients with a history of other malignant tumors;
  • Presence of oral mucositis at baseline;
  • Malnutrition at baseline;
  • Patients who cannot eat the required amount of food at baseline and require parenteral or enteral nutrition;
  • Inability to eat soft solid foods at baseline;
  • History of human immunodeficiency virus (HIV) or active hepatitis B/C virus infection;
  • Participation in other intervention clinical studies within one month;
  • Subjects deemed by the investigator to have other factors that may force them to terminate the study, such as having other serious illnesses (including mental illnesses) that require concomitant treatment, significantly abnormal laboratory test results, or family or social factors that may affect subject safety or data collection.

Quoted from ClinicalTrials.gov, NCT05892354, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05892354, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05892354